Prevention and Adjuvant Therapy in Breast Cancer

Faithlore P. Gardner, Edith A. Perez

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter presents a series of questions and answers on prevention and adjuvant therapy in breast cancer. It commences with a discourse on best strategies for breast cancer prevention in postmenopausal women, and ends with the optimal adjuvant approach for patients with resected HER2-positive invasive breast cancer. The chapter also discusses on the role of CYP2D6 in the efficacy and tolerability of tamoxifen in the chemoprevention setting, best adjuvant endocrine therapy for patients with hormone-positive invasive breast cancer, and real cardiovascular risk of anthracyclines used for the treatment of breast cancer.

Original languageEnglish (US)
Title of host publicationCancer Consult: Expertise for Clinical Practice
PublisherWiley Blackwell
Pages523-531
Number of pages9
ISBN (Print)9781118589199, 9781118589212
DOIs
StatePublished - Jun 20 2014

Keywords

  • Adjuvant endocrine therapy
  • Anthracyclines
  • Breast cancer
  • CYP2D6

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Prevention and Adjuvant Therapy in Breast Cancer'. Together they form a unique fingerprint.

  • Cite this

    Gardner, F. P., & Perez, E. A. (2014). Prevention and Adjuvant Therapy in Breast Cancer. In Cancer Consult: Expertise for Clinical Practice (pp. 523-531). Wiley Blackwell. https://doi.org/10.1002/9781118589199.ch81